These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34254125)

  • 21. Potential of mean force and molecular dynamics study on the transient interactions between α and β synuclein that drive inhibition of α-synuclein aggregation.
    Sanjeev A; Sahu RK; Mattaparthi VSK
    J Biomol Struct Dyn; 2017 Nov; 35(15):3342-3353. PubMed ID: 27809690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crowded organelles, lipid accumulation, and abnormal membrane tubulation in cellular models of enhanced α-synuclein membrane interaction.
    Ericsson M; von Saucken V; Newman AJ; Doehr L; Hoesch C; Kim TE; Dettmer U
    Brain Res; 2021 May; 1758():147349. PubMed ID: 33571519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies.
    Sekigawa A; Takamatsu Y; Sekiyama K; Hashimoto M
    Biomolecules; 2015 May; 5(2):1000-11. PubMed ID: 25996784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in the binding of copper(I) to α- and β-synuclein.
    De Ricco R; Valensin D; Dell'Acqua S; Casella L; Gaggelli E; Valensin G; Bubacco L; Mangani S
    Inorg Chem; 2015 Jan; 54(1):265-72. PubMed ID: 25495902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synuclein Family Members Prevent Membrane Damage by Counteracting α-Synuclein Aggregation.
    Scheibe C; Karreman C; Schildknecht S; Leist M; Hauser K
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation of N-terminally acetylated α-synuclein.
    O'Leary EI; Jiang Z; Strub MP; Lee JC
    J Biol Chem; 2018 Jul; 293(28):11195-11205. PubMed ID: 29853639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible alterations in β-Synuclein, the non-amyloidogenic homologue of α-Synuclein, during progression of sporadic α-synucleinopathies.
    Fujita M; Sekigawa A; Sekiyama K; Takamatsu Y; Hashimoto M
    Int J Mol Sci; 2012; 13(9):11584-11592. PubMed ID: 23109872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioinorganic Chemistry of Parkinson's Disease: Affinity and Structural Features of Cu(I) Binding to the Full-Length β-Synuclein Protein.
    Miotto MC; Pavese MD; Quintanar L; Zweckstetter M; Griesinger C; Fernández CO
    Inorg Chem; 2017 Sep; 56(17):10387-10395. PubMed ID: 28820253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of intramolecular dynamics and conformations of α-, β- and γ-synuclein.
    Ducas VC; Rhoades E
    PLoS One; 2014; 9(1):e86983. PubMed ID: 24489820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prion-like C-Terminal Domain of TDP-43 and α-Synuclein Interact Synergistically to Generate Neurotoxic Hybrid Fibrils.
    Dhakal S; Wyant CE; George HE; Morgan SE; Rangachari V
    J Mol Biol; 2021 May; 433(10):166953. PubMed ID: 33771571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The synucleins are a family of redox-active copper binding proteins.
    Davies P; Wang X; Sarell CJ; Drewett A; Marken F; Viles JH; Brown DR
    Biochemistry; 2011 Jan; 50(1):37-47. PubMed ID: 21117662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid Alpha-Synuclein Toxicity in a Neural Cell Model and Its Rescue by a Stearoyl-CoA Desaturase Inhibitor.
    Terry-Kantor E; Tripathi A; Imberdis T; LaVoie ZM; Ho GPH; Selkoe D; Fanning S; Ramalingam N; Dettmer U
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vesicle trafficking and lipid metabolism in synucleinopathy.
    Fanning S; Selkoe D; Dettmer U
    Acta Neuropathol; 2021 Apr; 141(4):491-510. PubMed ID: 32607605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased Dynamics of α-Synuclein Fibrils by β-Synuclein Leads to Reduced Seeding and Cytotoxicity.
    Yang X; Williams JK; Yan R; Mouradian MM; Baum J
    Sci Rep; 2019 Nov; 9(1):17579. PubMed ID: 31772376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MUFA synthesis and stearoyl-CoA desaturase as a new pharmacological target for modulation of lipid and alpha-synuclein interaction against Parkinson's disease synucleinopathy.
    Kula J; Kuter KZ
    Neuropharmacology; 2024 May; 249():109865. PubMed ID: 38342377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Residual structure, backbone dynamics, and interactions within the synuclein family.
    Sung YH; Eliezer D
    J Mol Biol; 2007 Sep; 372(3):689-707. PubMed ID: 17681534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. β-synuclein aggregates and induces neurodegeneration in dopaminergic neurons.
    Taschenberger G; Toloe J; Tereshchenko J; Akerboom J; Wales P; Benz R; Becker S; Outeiro TF; Looger LL; Bähr M; Zweckstetter M; Kügler S
    Ann Neurol; 2013 Jul; 74(1):109-18. PubMed ID: 23536356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss in Toxic Function of Aggregates of α -Synuclein Mutants by a β-Synuclein Derived Peptide.
    Mohammadi S; Nikkhah M; Hosseinkhani S
    Protein Pept Lett; 2017; 24(8):757-764. PubMed ID: 28820063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's disease: proteinopathy or lipidopathy?
    Fanning S; Selkoe D; Dettmer U
    NPJ Parkinsons Dis; 2020; 6():3. PubMed ID: 31909184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.